Matthew Korenberg - 30 Jun 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
EVP,Finance & Strategy and CFO
Signature
By: Charles S. Berkman For: Matthew E. Korenberg
Issuer symbol
LGND
Transactions as of
30 Jun 2022
Transactions value $
$12,437
Form type
4
Filing time
06 Jul 2022, 20:00:29 UTC
Previous filing
14 Jun 2022
Next filing
04 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Other $12.4K +164 +0.31% $75.84 52.5K 30 Jun 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares acquired under Ligand's employee stock purchase plan. Voluntary reporting exemption under Rule 16b-3(c).